Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
出版年份 2021 全文链接
标题
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
作者
关键词
-
出版物
Pharmaceuticals
Volume 14, Issue 8, Pages 710
出版商
MDPI AG
发表日期
2021-07-23
DOI
10.3390/ph14080710
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Umbralisib: First Approval
- (2021) Sohita Dhillon et al. DRUGS
- Trilaciclib: First Approval
- (2021) Sohita Dhillon DRUGS
- Kinase drug discovery 20 years after imatinib: progress and future directions
- (2021) Philip Cohen et al. NATURE REVIEWS DRUG DISCOVERY
- Zanubrutinib: First Approval
- (2020) Yahiya Y. Syed DRUGS
- Avapritinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Tepotinib: First Approval
- (2020) Anthony Markham DRUGS
- Pemigatinib: First Approval
- (2020) Sheridan M. Hoy DRUGS
- The discovery and development of binimetinib for the treatment of melanoma
- (2020) Brian Tran et al. Expert Opinion on Drug Discovery
- Tucatinib: First Approval
- (2020) Arnold Lee DRUGS
- Selumetinib: First Approval
- (2020) Anthony Markham et al. DRUGS
- Selpercatinib: First Approval
- (2020) Anthony Markham DRUGS
- Capmatinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Ripretinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Fyn Tyrosine Kinase as Harmonizing Factor in Neuronal Functions and Dysfunctions
- (2020) Carmela Matrone et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases
- (2020) Marija Buljan et al. MOLECULAR CELL
- Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
- (2020) Shanada Monestime et al. DRUGS IN R&D
- An Overview of the Role of Calcium/Calmodulin-Dependent Protein Kinase in Cardiorenal Syndrome
- (2020) Carolina Victoria Cruz Junho et al. Frontiers in Physiology
- Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma
- (2020) Gehan Botrus et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Protein Kinase Inhibitor Peptide as a Tool to Specifically Inhibit Protein Kinase A
- (2020) Chong Liu et al. Frontiers in Physiology
- Larotrectinib: First Global Approval
- (2019) Lesley J. Scott DRUGS
- Lorlatinib: First Global Approval
- (2019) Yahiya Y. Syed DRUGS
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
- (2019) Robert Ali et al. Drug Design Development and Therapy
- Properties of FDA-approved small molecule protein kinase inhibitors
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Gilteritinib: First Global Approval
- (2019) Sohita Dhillon DRUGS
- Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment
- (2019) Monica Capozzi et al. Cancer Management and Research
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- Entrectinib: First Global Approval
- (2019) Zaina T. Al-Salama et al. DRUGS
- Fedratinib: First Approval
- (2019) Hannah A. Blair DRUGS
- Pharmacological research and cancer: A call to arms
- (2019) Keiran S.M. Smalley PHARMACOLOGICAL RESEARCH
- Upadacitinib: First Approval
- (2019) Sean Duggan et al. DRUGS
- Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma
- (2019) Fangmin Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The Landscape of Atypical and Eukaryotic Protein Kinases
- (2019) Georgi K. Kanev et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Preclinical and clinical development of palbociclib and future perspectives
- (2018) E. Martínez de Dueñas et al. Clinical & Translational Oncology
- Development of encorafenib for BRAF-mutated advanced melanoma
- (2018) Peter Koelblinger et al. CURRENT OPINION IN ONCOLOGY
- Evolution, dynamics and dysregulation of kinase signalling
- (2018) David Ochoa et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Fostamatinib: First Global Approval
- (2018) Anthony Markham DRUGS
- Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib
- (2018) Linyi Liu et al. Future Medicinal Chemistry
- Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
- (2018) Cheng-Wen Lin et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Unexplored therapeutic opportunities in the human genome
- (2018) Tudor I. Oprea et al. NATURE REVIEWS DRUG DISCOVERY
- Kinase inhibitors: the road ahead
- (2018) Fleur M. Ferguson et al. NATURE REVIEWS DRUG DISCOVERY
- State of the Art of Pharmaceutical Solid Forms: from Crystal Property Issues to Nanocrystals Formulation
- (2018) Brice Martin Couillaud et al. ChemMedChem
- Dacomitinib: First Global Approval
- (2018) Matt Shirley DRUGS
- Duvelisib: First Global Approval
- (2018) Hannah A. Blair DRUGS
- Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer
- (2018) Arnaud Jeanson et al. Expert Review of Anticancer Therapy
- Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer
- (2017) Giuseppe Curigliano et al. Expert Opinion on Drug Metabolism & Toxicology
- The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma
- (2017) Sarah Knispel et al. Expert Opinion On Drug Safety
- Nintedanib in ovarian cancer
- (2017) Saira Khalique et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib
- (2017) Tommaso De Pas et al. Future Oncology
- Insane in the membrane: a structural perspective of MLKL function in necroptosis
- (2017) Emma J Petrie et al. IMMUNOLOGY AND CELL BIOLOGY
- The target landscape of clinical kinase drugs
- (2017) Susan Klaeger et al. SCIENCE
- The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
- (2016) Alex Kim et al. Expert Opinion on Drug Discovery
- The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
- (2016) Srividya Srinivasamaharaj et al. Expert Review of Anticancer Therapy
- Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
- (2016) Wolfgang Brückl et al. Expert Review of Anticancer Therapy
- Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
- (2016) Giuseppe Procopio et al. Drug Design Development and Therapy
- Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma
- (2015) Yousef Zakharia et al. Expert Opinion on Drug Discovery
- Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib
- (2015) Benjamin Carlisle et al. JNCI-Journal of the National Cancer Institute
- Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib
- (2015) Benjamin Carlisle et al. JNCI-Journal of the National Cancer Institute
- Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis
- (2014) Kirandeep Kaur et al. CLINICAL THERAPEUTICS
- The preclinical development of regorafenib for the treatment of colorectal cancer
- (2014) Koh Miura et al. Expert Opinion on Drug Discovery
- Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis
- (2014) Birgit Schittek et al. Molecular Cancer
- AGC protein kinases: From structural mechanism of regulation to allosteric drug development for the treatment of human diseases
- (2013) José M. Arencibia et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
- (2013) Robert Roskoski Expert Opinion on Drug Discovery
- The discovery and development of vandetanib for the treatment of thyroid cancer
- (2013) Michael W Sim et al. Expert Opinion on Drug Discovery
- Cancer Drugs in the United States: Justum Pretium—The Just Price
- (2013) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma
- (2012) A. Guarini et al. CURRENT MEDICINAL CHEMISTRY
- Temsirolimus: a safety and efficacy review
- (2012) Ronald M. Bukowski Expert Opinion On Drug Safety
- Lapatinib and renal cell carcinoma
- (2012) Marine Gross-Goupil et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Nilotinib as first-line therapy for chronic myeloid leukemia
- (2012) A Vaid INDIAN JOURNAL OF CANCER
- The secret life of kinases: functions beyond catalysis
- (2011) Jens Rauch et al. Cell Communication and Signaling
- A potential role of ruxolitinib in leukemia
- (2011) Kiran Naqvi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Pazopanib: Clinical development of a potent anti-angiogenic drug
- (2010) Fabio A.B. Schutz et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Protein kinase signaling networks in cancer
- (2010) John Brognard et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- (2010) Hisao Masai Drug Design Development and Therapy
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started